Changchun High-Tech Industry (Group) Co., Ltd. (SHE:000661)
China · Delayed Price · Currency is CNY 85.60
+0.49 (0.58%)
Apr 28, 2026, 3:04 PM CST
SHE:000661 Revenue
Changchun High-Tech Industry (Group) had revenue of 2.59B CNY in the quarter ending March 31, 2026, a decrease of -13.69%. This brings the company's revenue in the last twelve months to 11.67B, down -12.14% year-over-year. In the year 2025, Changchun High-Tech Industry (Group) had annual revenue of 12.08B, down -10.27%.
Revenue (ttm)
11.67B
Revenue Growth
-12.14%
P/S Ratio
2.93
Revenue / Employee
1.16M
Employees
11,547
Market Cap
34.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.08B | -1.38B | -10.27% |
| Dec 31, 2024 | 13.47B | -1.10B | -7.55% |
| Dec 31, 2023 | 14.57B | 1.94B | 15.35% |
| Jan 1, 2023 | 12.63B | 1.88B | 17.50% |
| Jan 1, 2022 | 10.75B | 2.17B | 25.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| China Resources Sanjiu Medical & Pharmaceutical | 32.88B |
| Humanwell Healthcare (Group) | 23.96B |
| Beijing Tongrentang | 17.26B |
| Livzon Pharmaceutical Group | 11.71B |
| Dong-E-E-Jiao | 6.80B |
| Shijiazhuang Yiling Pharmaceutical | 6.01B |
| Hubei Jumpcan Pharmaceutical | 5.90B |
| Kangmei Pharmaceutical | 5.25B |
Changchun High-Tech Industry (Group) News
- 4 months ago - Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion - South China Morning Post